SIGA Technologies (SIGA) AGM 2026 summary

Opening remarks and agenda

• CEO welcomed attendees, introduced board members, senior management, and external auditors, and outlined the meeting's agenda and procedures.

• Meeting held with proper notice, with proxy materials and voting instructions provided to shareholders.

• Quorum established with over 35.8 million shares represented, enabling business to proceed.

Financial performance review

• Reported $95 million in total revenues and $88 million in product sales for 2025.

• Delivered 79 million units of TPOXX to the U.S. Strategic National Stockpile and 6 million to an international customer.

• Returned $43 million to shareholders through special cash dividends in both 2025 and 2026.

Strategic initiatives and plans

• Advancing pediatric formulation of TPOXX and planning FDA submission for post-exposure prophylactic use within 12 months.

• Secured $27 million in U.S. government funding for pediatric and IV TPOXX development.

• Ongoing engagement with the U.S. government for a new procurement contract.